What "FDA-approved GLP-1" actually means
FDA approval attaches to a specific drug product, at a specific dose and form, made by a specific manufacturer, for a specific use in a specific population. The FDA doesn't approve "GLP-1s" the way you'd approve a whole category. It approves Wegovy 2.4 mg injection from Novo Nordisk for chronic weight management in adults with obesity. Every word in that sentence matters.
That's why every confusing GLP-1 claim you'll ever see falls into one of five buckets:
| When you see this | What it actually means | FDA-approved? | What to verify |
|---|---|---|---|
| "Wegovy is FDA-approved for weight loss" | Specific semaglutide product, approved for chronic weight management at the labeled dose | ✅ Yes — for the labeled use | Match the label to your intended use |
| "Ozempic for weight loss" | Approved product, but weight-loss-only use is off-label. Ozempic is approved for type 2 diabetes | ⚠️ Product yes; this use no | Whether your clinician is prescribing off-label on purpose |
| "Mounjaro for weight loss" | Mounjaro is approved for T2D. The same molecule (tirzepatide) is sold as Zepbound for weight management | ⚠️ Mounjaro yes for T2D; Zepbound yes for weight | Which brand the prescription is actually for |
| "Compounded semaglutide" or "compounded tirzepatide" | Made by a pharmacy under compounding rules — not reviewed by FDA for safety, effectiveness, or quality | ❌ No | Pharmacy identity, clinical reason, source of the active ingredient |
| "Generic Ozempic" / "research peptide GLP-1" / "FDA-registered pharmacy GLP-1" | Marketing shortcuts that usually don't survive a quick check | ❌ Almost always no | Drugs@FDA database for an actual approval entry |
The trap most patients fall into
Patients hear "Ozempic" and "Wegovy" and think same drug, same approval, same story. They are the same molecule (semaglutide) made by the same company (Novo Nordisk). But they are two separate FDA-approved products with two separate labels, two separate doses, and two separate approved uses.
- • Ozempic — approved for type 2 diabetes, with later indications for cardiovascular and kidney risk reduction in adults with T2D.
- • Wegovy — approved for chronic weight management, with later indications for cardiovascular risk reduction and noncirrhotic MASH.
The same trap exists with Mounjaro and Zepbound (both tirzepatide, both Eli Lilly) and with Wegovy injection / Wegovy pill / Wegovy HD — three FDA-approved Novo Nordisk products built around semaglutide, each with its own application, dose, route, and review.
How does a GLP-1 get FDA approved step by step?
The standard pathway has seven stages: preclinical research, the IND application, Phase 1, Phase 2, Phase 3, the NDA, and post-market surveillance. It takes 8 to 15 years from lab discovery to your pharmacy. Each step has a job. Skipping it isn't a shortcut — it moves the product into a different regulatory category.
Step 1 — Preclinical research (lab and animal studies)
3–6 yearsBefore any human takes a new GLP-1, the sponsor spends years on lab work. They map how the molecule binds to the GLP-1 receptor, study how the body absorbs and clears it, and run safety tests in animals to flag problems before humans are exposed.
For GLP-1s, this is where the thyroid C-cell tumor signal was first seen in rodents — the reason many current GLP-1 products including Wegovy, Mounjaro, and Foundayo carry boxed warnings about medullary thyroid carcinoma (MTC), and why long-acting GLP-1 approvals have included long-term postmarketing surveillance commitments.
Step 2 — The IND application (asking permission to test in humans)
30-day FDA reviewThe Investigational New Drug application (IND) is the sponsor's package to FDA explaining the science so far and asking permission to start human trials. It includes the preclinical data, the manufacturing details, the proposed trial protocol, and the people who'll run it.
FDA has 30 days to review the IND. If they have safety concerns, they can issue a clinical hold and stop trials before they start.
Step 3 — Phase 1 (small safety trials)
~1 year, 20–80 peoplePer FDA, Phase 1 typically involves 20 to 80 people, often healthy volunteers. The job is to figure out the basics: how the drug behaves in the body, what doses are tolerable, what side effects appear first. For GLP-1s, this is where the gastrointestinal side effects (nausea, vomiting) first show up in humans.
Step 4 — Phase 2 (testing in patients)
1–2 years, up to ~300 patientsPhase 2 typically involves a few dozen to about 300 patients with the actual condition. This is where you find out: Does it actually work? Does it lower A1C in people with diabetes, or produce weight loss in people with obesity? And what's the right dose — not the maximum tolerable, but where benefit and side effects balance.
Phase 2 is where most candidate drugs die.
Step 5 — Phase 3 (the big trials)
2–4 years, hundreds to thousands of patientsPhase 3 typically involves several hundred to about 3,000 people, but GLP-1 programs are often much larger. Pivotal Phase 3 trials usually run 52 to 72 weeks, randomized drug versus placebo or active comparator.
Step 6 — The NDA (asking permission to sell)
10–12 months standard; 6 months Priority Review; 1–2 months CNPVIf Phase 3 succeeds, the sponsor submits a New Drug Application — usually thousands of pages — to FDA's Center for Drug Evaluation and Research (CDER). The NDA bundles all evidence: preclinical data, all trial data, manufacturing details (chemistry, manufacturing, and controls), proposed labeling, and a risk-management plan.
At the end, FDA approves, issues a Complete Response Letter asking for fixes, or denies. Ozempic's Advisory Committee voted 16-0 in favor in October 2017, six weeks before its December 5, 2017 approval.
Step 7 — Post-market monitoring
Ongoing after approvalApproval isn't the finish line. FDA keeps tracking safety through MedWatch (the adverse-event reporting system), FAERS (FDA Adverse Event Reporting System database), and REMS programs where applicable.
For long-acting GLP-1s, postmarketing requirements have included a long-term medullary thyroid carcinoma registry first established for Victoza in 2010, added to by Ozempic and others upon each approval. FDA can — and does — withdraw approvals when post-market evidence justifies it.
How big were the actual Phase 3 GLP-1 programs?
- • Wegovy STEP program (2021): ~4,500 adults across four trials
- • Ozempic SUSTAIN program (2017): ~8,000 adults across the full program
- • Mounjaro SURPASS program (2022): ~6,200 adults
- • Zepbound SURMOUNT-1 (2023): 2,539 adults in one pivotal trial alone
- • Wegovy SELECT trial (cardiovascular indication, 2024): ~17,600 adults
- • Foundayo Trials 1 and 2 (2026): 3,127 adults without diabetes + 1,613 adults with type 2 diabetes
Almost every weight-loss percentage, A1C reduction, or cardiovascular benefit number you've ever read about a GLP-1 came from one of these Phase 3 programs.
Every major FDA-approved GLP-1 and the trial it was approved on
Built by cross-referencing FDA approval letters, Drugs@FDA, FDA press releases, sponsor investor disclosures. Where press-release figures differ from the FDA label, we use the FDA label number. Last verified: May 19, 2026.
| Drug (brand) | Generic | First approval | Initial indication | Pathway | Pivotal trial(s) | FDA-label headline result |
|---|---|---|---|---|---|---|
| Byetta | exenatide | Apr 28, 2005 | Type 2 diabetes | Standard NDA | AMIGO program (~1,400) | First GLP-1 ever approved |
| Victoza | liraglutide | Jan 25, 2010 | Type 2 diabetes | Standard NDA | LEAD 1–6 (~6,500) | A1C reduction vs. comparators |
| Bydureon | exenatide ER | Jan 27, 2012 | Type 2 diabetes | Standard NDA | DURATION (~6,000) | Once-weekly dosing established |
| Tanzeum | albiglutide | Apr 15, 2014 | Type 2 diabetes | Standard BLA | HARMONY (~5,000) | Withdrawn 2018 (commercial decision) |
| Trulicity | dulaglutide | Sep 18, 2014 | Type 2 diabetes | Standard BLA | AWARD (~5,000) | Weekly A1C reduction |
| Saxenda | liraglutide 3.0 mg | Dec 23, 2014 | Chronic weight management | Standard NDA | SCALE (~5,000) | ~8% mean weight loss at 56 weeks |
| Adlyxin | lixisenatide | Jul 27, 2016 | Type 2 diabetes | Standard NDA | GetGoal + ELIXA (~6,000) | CV non-inferiority shown |
| Ozempic | semaglutide inj. | Dec 5, 2017 | Type 2 diabetes | Standard NDA; AdCom 16-0 | SUSTAIN (~8,000); SUSTAIN 6: 3,297 | A1C reduction; 26% MACE risk reduction in SUSTAIN 6 |
| Rybelsus | semaglutide oral | Sep 20, 2019 | Type 2 diabetes | Standard NDA | PIONEER (~9,500) | First oral GLP-1 |
| Wegovy (2.4 mg inj.) | semaglutide | Jun 4, 2021 | Chronic weight management | Priority Review | STEP 1–4 (~4,500) | ~15% mean weight loss at 68 weeks vs. 2.4% placebo |
| Mounjaro | tirzepatide | May 13, 2022 | Type 2 diabetes | Priority Review | SURPASS 1–5 (~6,200) | SURPASS-2: A1C −2.0–2.3%; weight loss −7.6 to −11.2 kg |
| Zepbound | tirzepatide | Nov 8, 2023 | Chronic weight management | Standard NDA | SURMOUNT 1–2 (2,539 in SURMOUNT-1) | 22.5% mean weight loss at 15 mg over 72 weeks |
| Wegovy pill | semaglutide oral 25 mg | Dec 22, 2025 | Weight management + MACE | Standard NDA | OASIS 4 Study 7 (307 randomized) | −13.6% body weight at Week 64 vs −2.4% placebo |
| Wegovy HD | semaglutide inj. 7.2 mg | Mar 19, 2026 | Chronic weight management (higher dose) | ⚡ CNPV — 54 days | STEP UP Study 8 (1,407) | −18.8% at Week 72 vs −15.5% on 2.4 mg vs −3.9% placebo |
| Foundayo | orforglipron | Apr 1, 2026 | Chronic weight management | ⚡ CNPV — 50 days (fastest NME since 2002) | Trial 1: 3,127; Trial 2: 1,613 | Trial 1: −11.1% at Week 72 vs −2.1% placebo |
For approval dates, label expansions, and the full chronology, see our GLP-1 FDA Approvals Timeline →
How long FDA approval takes — and why "50 days" doesn't mean what people think
Drug development takes 8 to 15 years. FDA review of the final application is a separate clock. When a headline says "FDA approved Foundayo in 50 days," it's measuring the review clock, not the development clock. Foundayo's two pivotal trials enrolled over 4,700 adults and ran for 72 weeks of treatment before the NDA hit FDA's desk. The "50 days" was the review of an already-completed evidence package — not 50 days of testing.
| Phase | Typical duration | What's actually happening |
|---|---|---|
| Preclinical | 3–6 years | Lab and animal studies |
| Phase 1 | ~1 year | Small human safety trial |
| Phase 2 | 1–2 years | Dose-finding in patients |
| Phase 3 | 2–4 years | Large efficacy and safety trials |
| NDA review (standard) | 10–12 months | FDA reviews the complete application |
| NDA review (Priority) | 6 months | Significant improvement in safety/effectiveness |
| NDA review (CNPV) | 1–2 months | New 2025 pilot for national priorities |
The four classical expedited pathways
Priority Review
Trigger: Drug offers significant improvement in safety or effectiveness
Benefit: 6-month review instead of 10
Wegovy's original 2021 approval; Mounjaro's 2022 approval
Fast Track
Trigger: Drug for a serious condition with unmet need
Benefit: More frequent FDA meetings + rolling review (FDA reviews parts of the NDA as submitted)
Commonly used in early GLP-1 development programs
Breakthrough Therapy
Trigger: Preliminary clinical evidence of substantial improvement over available therapy
Benefit: All Fast Track benefits + intensive guidance from FDA senior staff
Higher bar — preliminary evidence of superiority required
Accelerated Approval
Trigger: Serious condition where the drug shows benefit on a surrogate endpoint rather than long-term clinical outcomes
Benefit: Earlier approval, but confirmatory post-approval trials are required
Wegovy's August 2025 MASH approval (liver fibrosis as surrogate endpoint)
Key distinction: Priority Review, Fast Track, and Breakthrough Therapy are designations — they change how the application gets handled. Accelerated Approval is an actual approval pathway that allows approval based on earlier evidence. Designations don't lower the evidence bar. Accelerated Approval changes which evidence counts. The CNPV pilot is something else entirely — it shortens review time but doesn't replace either category.
Why two GLP-1s were approved in under 60 days — the CNPV program
The Commissioner's National Priority Voucher (CNPV) program is a new FDA pilot, announced by Commissioner Marty Makary on June 17, 2025, that targets a 1-to-2-month review window for drugs aligned with U.S. national health priorities. As of May 19, 2026, FDA has issued seven approvals under CNPV, including two GLP-1 weight-loss drugs: Wegovy HD (54 days from filing) and Foundayo (50 days from filing).
The five CNPV priority pillars
- 1.Public health crisis response
- 2.Innovative breakthrough therapies
- 3.Large unmet medical needs
- 4.Onshoring and supply chain resilience (domestic manufacturing)
- 5.Affordability improvements
Wegovy HD — 4th CNPV approval
📅 Submitted: November 25, 2025
✅ Approved: March 19, 2026 — 54 days from filing
Pivotal evidence: STEP UP Study 8 (1,407 adults); STEP UP T2D Study 9
FDA-label result: −18.8% body-weight change at Week 72 vs −15.5% with 2.4 mg vs −3.9% placebo
Foundayo — fastest NME since 2002
📅 Submitted: January 20, 2026
✅ Approved: April 1, 2026 — 50 days from filing
Pivotal evidence: Trial 1: 3,127 adults; Trial 2: 1,613 adults with T2D
FDA-label result: Trial 1: −11.1% at Week 72 vs −2.1% placebo
The honest critique
- • The American Action Forum has argued that CNPV's criteria are broader and less clinically grounded than the classical pathways — vouchers are awarded based on alignment with "national priorities" (including domestic manufacturing and affordability), not purely on disease severity or unmet medical need.
- • Reuters reported in early 2026 that FDA delayed two drug reviews under the voucher program after raising safety and efficacy concerns — suggesting the agency isn't rubber-stamping applications, but also that approval isn't guaranteed.
- • A public hearing was held June 4, 2026 to gather feedback on eligibility criteria, voucher selection, and program implementation.
Our position: CNPV has produced legitimate approvals so far, but the program is young and the eligibility framework is broader than the older pathways. Patients are right to ask whether political alignment and clinical evidence are equally rigorous filters.
Label expansions — when one approval becomes many
A drug's FDA approval can grow over time when the sponsor runs new trials and submits a supplemental New Drug Application (sNDA). Each new indication needs its own pivotal evidence, even when the molecule is the same. This is how Wegovy went from "weight management" in 2021 to "weight management + cardiovascular risk + MASH" by 2026 — three separate approvals, three separate trials, three separate FDA reviews.
| Drug | Original approval | Expansion | Date | Trial behind it |
|---|---|---|---|---|
| Ozempic | T2D / 2017 | CV risk reduction in T2D + heart disease | Jan 16, 2020 | SUSTAIN 6 |
| Ozempic | T2D / 2017 | Higher dose (2 mg) | Mar 28, 2022 | SUSTAIN FORTE |
| Ozempic | T2D / 2017 | CKD-related kidney protection | Jan 28, 2025 | FLOW |
| Wegovy | Obesity / 2021 | Adolescents 12+ | Dec 23, 2022 | STEP TEENS |
| Wegovy | Obesity / 2021 | CV risk reduction in CVD + overweight/obesity | Mar 8, 2024 | SELECT (~17,600 adults) |
| Wegovy | Obesity / 2021 | Noncirrhotic MASH (Accelerated Approval) | Aug 15, 2025 | ESSENCE Part 1 |
| Rybelsus | T2D / 2019 | CV risk reduction in T2D + elevated CV risk | Oct 2025 | SOUL |
| Mounjaro | T2D / 2022 | Pediatric T2D (10+) | Dec 19, 2025 | SURPASS-PEDS |
| Zepbound | Obesity / 2023 | Moderate-to-severe obstructive sleep apnea | Dec 20, 2024 | SURMOUNT-OSA |
It's not the molecule getting approved for everything. It's individual products earning individual indications, one trial at a time.
FDA-approved vs. compounded vs. off-label vs. generic — the four-way distinction
FDA-approved
A finished drug product (like Wegovy injection 2.4 mg) that has gone through preclinical, IND, Phase 1/2/3, NDA review, and FDA labeling. The FDA has signed off on safety, effectiveness, and manufacturing.
Off-label use
A licensed clinician prescribes an FDA-approved product for a use, dose, or population outside the approved label. The product itself is still FDA-approved. The specific use isn't. Off-label prescribing is legal under U.S. law — but manufacturers can't market the drug for off-label uses, and insurance often won't cover it. Example: Ozempic prescribed for weight loss in someone without diabetes.
Compounded drug
A drug prepared by a licensed compounding pharmacy under sections 503A (traditional) or 503B (outsourcing facility) of the Federal Food, Drug, and Cosmetic Act. Not FDA-approved as a finished product. FDA does not review them for safety, effectiveness, or quality before they reach patients. The FDA declared semaglutide and tirzepatide shortages resolved in 2024–2025, narrowing the legal grounds for compounding at scale. FDA has issued warning letters to dozens of telehealth companies over misleading marketing of compounded GLP-1s.
Generic
A copy of an FDA-approved brand drug that has gone through an Abbreviated New Drug Application (ANDA). The generic must be bioequivalent to the brand and meet the same manufacturing standards. As of May 19, 2026: generic exenatide (Amneal, November 2024), generic liraglutide referencing Victoza (Hikma, December 23, 2024), and generic liraglutide referencing Saxenda (Teva, August 2025). There is no FDA-approved generic semaglutide or tirzepatide.
The side-by-side that ends most arguments
| FDA-approved brand | FDA-approved generic | Compounded | Off-label use | |
|---|---|---|---|---|
| Pre-market FDA review | Full NDA | Abbreviated NDA (ANDA) | None | Underlying product was reviewed; this use wasn't |
| FDA manufacturing inspection | Application-linked + routine inspection | Application-linked + routine inspection | State board (503A); FDA inspects 503B | Same as the underlying product |
| FDA-approved labeling | Yes | Yes (matches brand) | No | Yes — but use is outside the label |
| Mandatory adverse-event reporting | Yes (MedWatch/FAERS) | Yes (MedWatch/FAERS) | Different oversight structure | Yes for the product |
| Real-world example | Wegovy 2.4 mg | Generic liraglutide (Hikma 2024, Teva 2025) | Compounded semaglutide | Ozempic for weight loss |
Not sure if your specific GLP-1 is FDA-approved or compounded? Our quiz routes you to verified FDA-approved providers.
Find My GLP-1 Path →Red flags in GLP-1 marketing claims
The pattern is consistent: the more a claim leans on adjacent regulatory language without naming a specific FDA-approved product, the more suspicious it should make you.
| Marketing phrase | Risk level | Why | Where to verify |
|---|---|---|---|
| "Wegovy FDA-approved for weight loss" | 🟢 Green if label matches | Verify brand and indication on the prescribing information | DailyMed / Drugs@FDA label Section 1 |
| "Ozempic for weight loss" | 🟡 Yellow | Approved product, off-label use. Clinician judgment applies | Drugs@FDA label vs. your intended use |
| "Compounded Wegovy" | 🔴 Red | Wegovy is a specific brand product. A compounded preparation is by definition not Wegovy | FDA compounding alerts |
| "Generic semaglutide" | 🔴 Red | No FDA-approved generic semaglutide as of May 2026 | Drugs@FDA / Orange Book |
| "Generic Zepbound" or "generic tirzepatide" | 🔴 Red | No FDA-approved generic tirzepatide as of May 2026 | Drugs@FDA / Orange Book |
| "FDA-registered pharmacy" | 🟡 Yellow | Facility registration ≠ drug approval | NDC Directory + Drugs@FDA |
| "Same active ingredient as Wegovy" | 🟡 Yellow | Almost always a compounded product framed to imply equivalence | FDA compounding alerts |
| "Research peptide" / "for research use only" | 🔴 Red | Investigational or unapproved. Not a regulated medicine | Not a medical product — do not treat as one |
| "No prescription required" | 🔴 Red | Prescription drugs require a prescription. Period | — |
| "Clinically tested" | 🟡 Yellow | Says nothing about FDA approval. Many things are tested and never approved | Ask which specific product was tested and where published |
What "FDA-registered pharmacy" really means
A pharmacy can register with the FDA — particularly 503B outsourcing facilities — and that registration is meaningful for facility oversight. But it is not drug approval. A registered facility can dispense compounded drugs that have never been FDA-reviewed. If a marketing page says "FDA-registered" and not "FDA-approved," they are almost always describing the facility, not the drug. Always ask which one.
How to verify any GLP-1 approval claim in 60 seconds
The fastest way is to search the FDA's Drugs@FDA database at accessdata.fda.gov/scripts/cder/daf/ using the exact brand name, then check the approval letter and current FDA-approved labeling against the use you're being offered. It takes about 60 seconds, costs nothing, and ends most arguments.
The 60-second checklist
- ☐Exact product name — Wegovy? Zepbound? Foundayo? Or "GLP-1 weight-loss program"? (The vague one is the red flag.)
- ☐Active ingredient — semaglutide, tirzepatide, liraglutide, orforglipron, or something else?
- ☐Route and form — injection? Tablet? Oral drops? Lozenge? Gummy? (Oral drops, lozenges, and gummy GLP-1s are not FDA-approved forms.)
- ☐Intended use — weight loss? Diabetes? Both?
- ☐Product source — manufacturer (Novo Nordisk, Eli Lilly)? Retail pharmacy? Compounding pharmacy? "Research vendor"?
- ☐Exact regulatory claim — "FDA-approved," "FDA-registered," "FDA-cleared," "compounded," "generic," "same as"?
The 5-step Drugs@FDA verification
- 1
Go to Drugs@FDA
Navigate to accessdata.fda.gov/scripts/cder/daf/
- 2
Search the brand name
Type the exact brand name (e.g., "Wegovy" or "Foundayo"). The database returns approval entries.
- 3
Click the result
You'll see the NDA number, the approval date, and a list of approval actions including any supplemental approvals (new indications, new doses, new formulations).
- 4
Open the Approval Letter (PDF)
This is FDA's signed letter to the sponsor. It states exactly what's approved.
- 5
Open the Current Labeling (PDF)
Section 1 of every approved drug's labeling is Indications and Usage. If the use you're being offered isn't listed there, the use isn't FDA-approved — even if the product is.
Is FDA approval the same as insurance approval?
No. FDA approval is a regulatory clearance to market a drug. Insurance approval is a separate decision by each payer about whether to cover the drug, for whom, under what conditions, and at what cost. A GLP-1 can be fully FDA-approved and still be denied by your insurance.
| FDA approval | Insurance approval | |
|---|---|---|
| Who decides | FDA (federal regulator) | Each insurance plan or pharmacy benefit manager |
| What it answers | Is the drug safe and effective enough to be sold for this use? | Will we pay for this drug for this patient? |
| What it requires | Clinical trial evidence, manufacturing data, label review | Plan formulary placement, diagnosis match, prior authorization, sometimes step therapy |
| What changes it | New evidence + sNDA | Annual formulary updates, plan negotiations, policy changes |
| GLP-1 example | Wegovy is FDA-approved for chronic weight management | Many plans only cover Wegovy if you also have a CV-disease indication or meet specific BMI + comorbidity criteria |
The practical rule: never assume FDA-approved = covered. Ask your plan, in writing, what's required for coverage of the specific GLP-1 your clinician wants to prescribe.
Need help finding a provider that works with your insurance and prescribes FDA-approved GLP-1s?
Take the Free 60-Second Quiz →What FDA approval does NOT prove
FDA approval is a floor, not a ceiling. It means a minimum bar of evidence has been met. Whether a specific GLP-1 is the right call for you is still a clinical conversation with your doctor.
❌ "The drug is safe for everyone"
It means benefits outweigh risks for the labeled population. Your specific situation might raise different concerns.
❌ "The drug is the best option"
FDA approval is a regulatory minimum, not a clinical maximum. There may be alternatives that fit your situation better.
❌ "Insurance will cover it"
Coverage rules vary by plan, indication, and prior-authorization requirements — completely separate from FDA status.
❌ "The drug is available today"
Approval doesn't guarantee supply. Wegovy and Mounjaro were in FDA-recognized shortages for over two years after their approvals.
❌ "The drug is affordable"
Approval and pricing are different conversations. Check the current manufacturer price, payer formulary, and pharmacy quote.
❌ "There are no side effects"
Many GLP-1 products carry boxed warnings about thyroid C-cell tumors and gastrointestinal side effects. Always check the current label.
❌ "You can stop without consequence"
SURMOUNT-4 showed patients who stopped tirzepatide regained about 14% of their body weight within a year.
What to ask before starting any GLP-1
Use these 10 questions when a clinician or telehealth program offers you a GLP-1. The right ones will answer them directly. The wrong ones will deflect.
- 1.What's the exact product name on the prescription? (Brand, dose, form)
- 2.Is it FDA-approved as a finished drug, or is it compounded?
- 3.What's the FDA-approved indication, and does my use match? (If not, it's off-label. That may still be appropriate — but you should know.)
- 4.What pharmacy fills the prescription, and is it the manufacturer or a compounding pharmacy?
- 5.Will the drug come in original manufacturer packaging? (For brand-name products, the answer should be yes.)
- 6.What are the boxed warnings on the current label, and do any apply to me? (Family history of medullary thyroid carcinoma is the big one for several products.)
- 7.What's the side-effect profile, and what do you do if I can't tolerate it?
- 8.What's the cost — list price, my insurance copay, and what happens if insurance denies?
- 9.What happens if there's a shortage? (Supply has been a real issue in this class.)
- 10.How do you monitor me after I start? (Lab work, weight checks, follow-up cadence)
If a provider can't or won't answer these clearly, that's the signal.
Where to check official FDA approval status
Marketing pages are not official sources. These are. Bookmark them.
| Question | Best source |
|---|---|
| Is this drug FDA-approved? | Drugs@FDA — accessdata.fda.gov/scripts/cder/daf/ |
| What's the approved indication, dosing, and warnings? | DailyMed — dailymed.nlm.nih.gov (NIH's database of current FDA-approved labeling) |
| Is there an FDA-approved generic? | FDA Orange Book — accessdata.fda.gov/scripts/cder/ob/ |
| When was this drug approved? | FDA press releases + Drugs@FDA approval history |
| What did the pivotal trials show? | FDA Drug Trials Snapshots — fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots |
| Is this drug currently in shortage? | FDA Drug Shortages database — accessdata.fda.gov/scripts/drugshortages/ |
| What's happening with compounded versions? | FDA compounding alerts and statements — fda.gov/drugs/human-drug-compounding |
| What does CNPV do and which drugs got vouchers? | FDA CNPV Program page — fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program |
What we actually verified for this page
We built this guide by cross-referencing FDA approval letters and current labels through Drugs@FDA, FDA press releases, sponsor investor disclosures (Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK), the Federal Register notice for the June 2026 CNPV public hearing, and the White House November 2025 fact sheet for pricing. Where a press-release figure differed from the FDA label number, we used the FDA-label number.
Verified ✅
✅Foundayo NDA submission date (January 20, 2026) and 50-day review timing, per the FDA approval letter
✅Wegovy HD sNDA submission date (November 25, 2025) and 54-day review timing, per the FDA approval letter
✅FDA-label weight-loss results for Wegovy pill (−13.6% at Week 64), Wegovy HD (−18.8% at Week 72 in Study 8), and Foundayo (−11.1% at Week 72 in Trial 1)
✅Foundayo Trial 1 (NCT05869903, 3,127 adults) and Trial 2 (NCT05872620, 1,613 adults) enrollment per the FDA label
✅Mounjaro SURPASS-2 results per the current FDA label
✅Three GLP-1 generic approvals: generic exenatide (Amneal, November 2024), generic liraglutide referencing Victoza (Hikma, December 23, 2024), and generic liraglutide referencing Saxenda (Teva, August 2025)
✅CNPV program structure, eligibility pillars, and June 4, 2026 public hearing date
✅November 2025 pricing agreement: $350/month for Ozempic and Wegovy; $346 average for Zepbound and Foundayo; $150 for initial-dose oral GLP-1s; $50 Medicare copay
Not verified ❌
❌Original sponsor names for older approvals (Byetta, Adlyxin) where ownership has changed — table uses current label holders
❌Internal FDA designations not publicly disclosed (e.g., whether every drug received Fast Track during development)
❌Forward-looking pipeline content beyond what sponsors and FDA have publicly announced
❌Whether any specific patient should or shouldn't take a specific GLP-1 — that's a clinical decision with your doctor
Update cadence: We review this page monthly and update sooner when FDA issues a major approval or guidance. Last verified: May 19, 2026. Next scheduled review: June 19, 2026.
Frequently asked questions about GLP-1 FDA approval
Why this page exists
We track GLP-1 pricing, access, and regulatory status full-time. We built this page because the question "Is this GLP-1 FDA-approved?" gets asked constantly, and the answer almost always hinges on a distinction (product vs. molecule, brand vs. compounded, on-label vs. off-label) that most pages don't bother to make. The five-bucket framework at the top is the framework we use ourselves when we evaluate any GLP-1 marketing claim.
For the full chronological list of every FDA-approved GLP-1 with dates, indications, and label expansions, see our GLP-1 FDA Approvals Timeline →
Not sure which FDA-approved GLP-1 is right for you?
Our free 60-second quiz routes you to verified FDA-approved providers based on your insurance, budget, and medication preference — no signup required.
Find My GLP-1 Path →